The table below provides the original cost, accumulated amortization and net book value by major intangible asset classification:


	Original Cost		Accumulated Amortization		Net Book Value
Definite-lived intangible assets
Distribution rights	$	62,787	$	(20,805)	$	41,982
Capitalized software	18,876		(12,818)		6,058
Intangible assets, net	81,663		(33,623)		48,040
Indefinite-lived intangible asset
Goodwill	21,208		—		21,208
Total as of December 31, 2025	$	102,871	$	(33,623)	$	69,248


	Original Cost		Accumulated Amortization		Net Book Value
Definite-lived intangible assets
Distribution rights	$	62,787	$	(17,580)	$	45,207
Capitalized software	13,317		(9,770)		3,547
Intangible assets, net	76,104		(27,350)		48,754
Indefinite-lived intangible asset
Goodwill	21,208		—		21,208
Total as of December 31, 2024	$	97,312	$	(27,350)	$	69,962

The following table outlines the estimated future amortization expense related to intangible assets held as of December 31, 2025 that are subject to amortization:


Fiscal year
2026	$	7,505
2027	4,810
2028	3,378
2029	3,211
2030	3,211
Thereafter	25,925
	$	48,040

Distribution rights represent the license and associated distribution rights to Jeuveau® and Evolysse™. For the year ended December 31, 2024, the Company capitalized $2,235 related to the license and distribution right to Evolysse™ nasolabial fold product in Europe, which is amortized on a straight-line basis over the estimated useful life of 15 years. No costs related to distribution rights were capitalized for the year ended December 31, 2025.

For the years ended December 31, 2025 and 2024, the Company capitalized $5,619 and $3,513, respectively, related to costs of computer software developed for internal use. The software is amortized over a two-year period using the straight-line method.

For the years ended December 31, 2025, 2024 and 2023, the Company recorded amortization expense related to intangible assets of $6,273, $4,104 and $4,072, respectively. These amounts were included in cost of goods sold and depreciation and amortization in the accompanying consolidated statements of operations and comprehensive loss.